Hormonal
A glucose disposal rate (GDR) below 5.6 mg/kgFFM+17.7 min during a 120 mU/m2·min hyperinsulinemic-euglycemic clamp identifies insulin resistance with 75% sensitivity and 71% specificity in white populations.
If you are undergoing metabolic testing, ask how your glucose disposal rate is normalized. For standard research clamps using high-dose insulin, a rate below 5.6 mg/kg fat-free mass per minute suggests insulin resistance. For routine clinical care, a HOMA-IR above 5.9, or between 2.8 and 5.9 combined with low HDL (<51 mg/dL), strongly predicts insulin resistance without needing a clamp.
A cutoff of 5.6 mg/kgFFM+17.7 z min provided the maximum theoretical sensitivity (75%) and specificity (71%) with an aROC of 80% for defining insulin resistance.
Why this rating
High-quality observational data from standardized clinical research center protocols (n=263), though limited to specific demographics.
Source
Defining Insulin Resistance From Hyperinsulinemic-Euglycemic Clamps
Charmaine S. Tam et al. · Diabetes Care · 2012
DOI 10.2337/dc11-2339
More from this paper
- Insulin resistance can be accurately predicted using routine clinical variables (HOMA-IR, HDL, fasting insulin) without performing a hyperinsulinemic-euglycemic clamp.Good
- A glucose disposal rate (GDR) below 5.3 mg/kgFFM+17.7 min during an 80 mU/m2·min hyperinsulinemic-euglycemic clamp identifies insulin resistance with 83% sensitivity and 96% specificity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →